PLoS ONE (Jan 2020)
Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer.
Abstract
BackgroundThe aim of this study was to determine the utility of the neutrophil-to-lymphocyte ratio (NLR) as a biomarker for predicting early-mortality (MethodsWe reviewed 118 medical records of females with mTNBC. The cut-off value for the NLR (ResultsThe median follow-up was 24 months. Females with NLR ≥2.5 had a poor overall survival compared to females with NLR ConclusionThe NLR is an accessible and reliable biomarker that predicts early mortality among females with mTNBC. Our results suggest that females with high NLR values have poor prognosis despite receiving standard chemotherapy. Health providers should evaluate the possibility to enroll these patients in novel immunotherapy trials.